Pipeline

Altheia Science develops innovative therapeutic approaches in autoimmune diseases and liquid tumours exploiting technology tools in cell and gene therapy generated over two decades of research in translational medicine.

 

Modulating the expression of PD-L1 onto patients’ hematopoietic stem and progenitor cells restores their therapeutic immune ability in eliminating autoreactive T lymphocytes, which are the root cause of the autoimmune disease.

 

Altheia Science has identified novel tumour-specific antigens that can serve as restricted targets for chimeric antigen receptor (CAR)-T cells, able to eliminate leukemic cells sparing healthy cells.

 

These approaches have the potential to drastically modify the natural history of diseases with high clinical impact in autoimmunity and liquid tumours, achieving safe and durable benefits for each patient.

Altheia Science’s pipeline exploits pioneering therapeutic tools for autoimmune diseases and cancer.

 

The modulation of PD-L1 expression at the molecular and protein level is key to devise advanced treatments. This can be achieved by first-in-class molecules controlling the PD-L1 pathway and/or by lentiviral vector-based engineering of patients’ hematopoietic stem cells.

 

Altheia Science’s approach intends to drastically modify the natural history of diseases with high clinical impact in autoimmunity and cancer by modulating PD-L1 expression, achieving tangible and durable benefit for each patient.

PIPELINE AT A GLANCE

(click on the image to zoom)